Passage Bio, Inc. (PASG) Stock

Passage Bio, Inc. (PASG) is a Healthcare stock trading at $4.38 (as of 2026-08-21), with a market capitalization of $14.09M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Passage Bio is a genetic medicines company developing gene therapy candidates for central nervous system disorders. Its pipeline includes AAV-based programs such as PBGM01 (infantile GM1), PBFT02 (FTD-GRN), PBKR03 (infantile Krabbe), and additional candidates for metachromatic leukodystrophy, ALS, and Charcot-Marie-Tooth disease type 2A, supported by research and development collaborations with the University of Pennsylvania Gene Therapy Program and Catalent Maryland.

Valuation — source: SEC EDGAR (first-party)
Price	$4.38
Market Cap	$14.09M
Price / Book	3.16

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$343000.00
Net Margin	-54048.4%

Valuation vs Sector & Industry
Sector P/E (Healthcare)	21.7
Industry P/E (Pharmaceutical Products)	17.2

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	Lynx1 Capital Management LP ($4.90M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	William Chou
Employees	60
Country	US
IPO Date	2020-02-28

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.